化学
生物利用度
药代动力学
药理学
苯并呋喃
口服
癌症
前药
结构-活动关系
铅化合物
癌症研究
降级(电信)
小分子
癌症治疗
乙酰化
口服剂量
作者
Zhimin Zhang,Yujie Chang,Li Teng,Cancan Cai,Xiaoyan Deng,Xiaohua Zhang,Jingwen E,Jiangqi He,Mengting Zhao,Dongzhou Liu
标识
DOI:10.1021/acs.jmedchem.6c01738
摘要
Abstract Targeted protein degradation of the translation termination factor GSPT1 is a promising cancer strategy. However, current cereblon-recruiting molecular glue degraders (MGDs) lack structural diversity, being mostly IMiD derivatives. To overcome resistance and improve drug-like properties, we report the rational, structure-guided design of a novel series of benzofuran-based GSPT1 MGDs. Extensive structure−activity relationship studies and optimization led to the discovery of highly potent, orally bioavailable degraders, highlighted by compounds C-3 and C-4. Both exhibited single-digit nanomolar GSPT1 degradation (DC50 = 2.81 and 1.91 nM) and robust selectivity over IMiD off-targets IKZF1 and SALL4. In vivo, oral administration (1−2 mg/kg) of C-3 and C-4 demonstrated favorable cross-species pharmacokinetics and achieved sustained tumor regression in NCI-H1155 and MDA-MB-468 xenograft models. With a maximum tolerated dose exceeding 100 mg/kg and no hematological toxicity, these benzofuran-based MGDs are highly promising preclinical candidates for solid tumors.
科研通智能强力驱动
Strongly Powered by AbleSci AI